Devices

By Guest Writer David Kliff, Publisher, Diabetic Investor: Although it has taken much longer than I anticipated, market dynamics are forcing companies to think differently and we are now on the verge of patients being prescribed diabetes management systems rather than individual pieces of the system.

Once given FDA approval, the Senseonics Eversence System will be the fourth CGMS available in the U.S. It was submitted to the FDA for premarket approval last October, supported by data from a 90-patient pivotal trial of the device. The trial followed adults with type 1 or type 2 diabetes over 90 days of CGM sensor wearing. This is an implantable CGM system that is currently approved in Europe. The sensor sits just under your skin and can stay there for anywhere from 90-180 days.

CGM will be available at lower price, without fingerstick calibration, and can be worn for 10 days with 12-hour warmup.

Sensor-augmented therapy can diminish hypoglycemia with the low-glucose suspend feature.

First Continuous Glucose Monitor that doesn’t require routine finger pricks.

Scott Abbott is the Director of Medical Development at Valeritas. He shares information from his presentation at the ADA on how the V-Go insulin delivery device can be used in the real world.

Dr. Scott Abbott discusses the V-Go wearable insulin delivery device, which is like a wearable insulin pen; it uses rapid-acting insulin and is approved as a pump-like device.

In this Exclusive Interview, Scott Abbott talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the use, benefits, and future of the V-Go insulin delivery system.

In part 1 of this Exclusive Interview, Scott Abbott talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about how the V-Go insulin delivery system can be used in diabetes patients in real world settings.

In part 2 of this Exclusive Interview, Scott Abbott explains how the V-Go insulin delivery device works in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.